PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCanagliflozin
Invokana(canagliflozin)
Invokamet, Invokana, Vokanamet (canagliflozin) is a small molecule pharmaceutical. Canagliflozin was first approved as Invokana on 2013-03-29. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Canagliflozin, Invokana (discontinued: Canagliflozin)
Combinations
Invokamet
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Canagliflozin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
INVOKAMETJohnson & JohnsonN-204353 RX2014-08-08
4 products, RLD, RS
INVOKAMET XRJohnson & JohnsonN-205879 RX2016-09-20
4 products, RLD, RS
Canagliflozin
Tradename
Company
Number
Date
Products
INVOKANAJohnson & JohnsonN-204042 RX2013-03-29
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
invokametNew Drug Application2018-06-21
invokamet invokamet xrNew Drug Application2026-08-24
invokanaNew Drug Application2026-09-21
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms
115768942030-07-06DP
Canagliflozin, Invokana, Janssen Pharms
79435822029-02-26DS, DPU-493, U-2441, U-2632
85132022027-12-03DS, DPU-493, U-2441, U-2632
79437882027-07-14DS, DP
82222192025-04-11U-493, U-2441, U-2632
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD16: Metformin and canagliflozin
— A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
— A10BK02: Canagliflozin
HCPCS
No data
Clinical
Clinical Trials
185 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1113723292696
Diabetes mellitusD003920EFO_0000400E08-E13341071033
ObesityD009765EFO_0001073E66.912—328
Chronic renal insufficiencyD051436—N18—21328
Cardiovascular diseasesD002318EFO_0000319I98——1247
Insulin resistanceD007333EFO_0002614E88.8191——416
Diabetic nephropathiesD003928EFO_0000401——12216
Type 1 diabetes mellitusD003922EFO_0001359E10—1—225
OverweightD050177—E66.3—2—114
AlbuminuriaD000419EFO_0004285R80.9—1—3—4
Show 25 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50——2—24
Coronary artery diseaseD003324—I25.1—11—12
ConfusionD003221—F44.89——1——1
Risk factorsD012307EFO_0003919———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——21———2
Breast neoplasmsD001943EFO_0003869C5012———2
Endometrial neoplasmsD016889EFO_0004230—12———2
StrokeD020521EFO_0000712I63.9—1———1
Head and neck neoplasmsD006258——11———1
Lung neoplasmsD008175—C34.9011———1
Acute kidney injuryD058186—N17—1———1
Peritoneal fibrosisD056627EFO_1001394——1———1
Endometrial hyperplasiaD004714—N85.0—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———47————47
Liver diseasesD008107EFO_0001421K70-K771———12
NeoplasmsD009369—C801———12
GlycosuriaD006029—R811————1
Therapeutic equivalencyD013810——1————1
Plasma volumeD010953——1————1
Hepatic insufficiencyD048550——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic ketoacidosisD016883EFO_1000897—————22
SepsisD018805EFO_0001420A41.9————11
Ischemic strokeD000083242——————11
Myocardial infarctionD009203EFO_0000612I21————11
Diabetes insipidusD003919—E23.2————11
KetosisD007662—R82.4————11
Prediabetic stateD011236EFO_1001121R73.03————11
HivD006678—O98.7————11
Acquired immunodeficiency syndromeD000163EFO_0000765B20————11
Fatty liverD005234EFO_0003934—————11
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCanagliflozin
INNcanagliflozin
Description
Canagliflozin is a C-glycosyl compound that is used (in its hemihydrate form) for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2. It has a role as a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor. It is a C-glycosyl compound, a member of thiophenes and an organofluorine compound.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O
Identifiers
PDB—
CAS-ID1589590-87-3
RxCUI—
ChEMBL IDCHEMBL4594217
ChEBI ID—
PubChem CID24812758
DrugBankDB08907
UNII ID6S49DGR869 (ChemIDplus, GSRS)
Target
Agency Approved
SLC5A2
SLC5A2
Organism
Homo sapiens
Gene name
SLC5A2
Gene synonyms
SGLT2
NCBI Gene ID
Protein name
sodium/glucose cotransporter 2
Protein synonyms
Low affinity sodium-glucose cotransporter, Na(+)/glucose cotransporter 2, solute carrier family 5 (sodium/glucose cotransporter), member 2, solute carrier family 5 (sodium/glucose transporter), member 2, Solute carrier family 5 member 2
Uniprot ID
Mouse ortholog
Slc5a2 (246787)
sodium/glucose cotransporter 2 (Q923I7)
Alternate
SLC5A1
SLC5A1
Organism
Homo sapiens
Gene name
SLC5A1
Gene synonyms
NAGT, SGLT1
NCBI Gene ID
Protein name
sodium/glucose cotransporter 1
Protein synonyms
High affinity sodium-glucose cotransporter, Na+/glucose cotransporter 1, solute carrier family 5 (sodium/glucose cotransporter), member 1, Solute carrier family 5 member 1
Uniprot ID
Mouse ortholog
Slc5a1 (20537)
sodium/glucose cotransporter 1 (Q8C3K6)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Canagliflozin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Invokamet, Invokamet invokamet xr
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
25,725 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use